What is clinical trial NCT07024784 studying?

NCT07024784 is a Phase 2 clinical trial evaluating IMGN151 for Gynecologic Cancers. The trial is sponsored by AbbVie and is currently recruiting.

What phase is the NCT07024784 clinical trial?

NCT07024784 is a Phase 2 clinical trial. Phase 3 trials are pivotal studies required before FDA approval, typically enrolling hundreds to thousands of participants to prove efficacy and safety.

Is NCT07024784 still recruiting participants?

The current enrollment status of NCT07024784 is: RECRUITING. The trial is actively enrolling — check ClinicalTrials.gov for eligibility criteria.

Who is the sponsor of clinical trial NCT07024784?

NCT07024784 is sponsored by AbbVie (ABBV). BiotechSign currently grades the sponsor a C (58/100) based on its composite pipeline strength and catalyst outlook.

Home›Trial›NCT07024784

NCT07024784Phase 2RECRUITING

A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

Study Summary

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety and tolerability of IMGN151 when given as monotherapy and in combination with other anti-cancer therapies in adult participants with gynecologic cancers. IMGN151 is an investigational drug being developed for the treatment of gynecologic cancers. Participants are placed in 1 of 4 groups, called treatment arms. Each group receives a different treatment. Around 377 participants with gynecologic cancers will be enrolled in the study at approximately 50 sites worldwide. Participants will receive intravenous infusions of IMGN151 as monotherapy or in combination with anti-cancer therapies according to their assigned study arm. In Arm A, participants will receive IMGN151 in combination with carboplatin on Day 1 of each cycle. In Arm B, participants will receive IMGN151 in combination with olaparib, twice a day (BID) on Day 1 of each cycle. In Arm C, participants will receive IMGN151 in combination with bevacizumab on Day 1 of each cycle. In Arm D, participants will receive IMGN151 as monotherapy on Day 1 of each cycle. In Arm E, participants will receive IMGN151 as monotherapy on Day 1 of each cycle. In Arm F, participants will receive IMGN151 as monotherapy on Day 1 of each cycle. The total study duration will be approximately 3 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and scans.

Conditions

Gynecologic Cancers Platinum-Sensitive Ovarian Cancer Fallopian Tube Cancer Primary Peritoneal Cancer (PSOC)

Interventions / Drugs

IMGN151 Carboplatin Bevacizumab Olaparib

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment377 participants

Primary Completion—

Lead SponsorAbbVie

Data Retrieved2026-04-11 02:51:51.325372+00:00

What This Trial Means for Biotech Investors

Trial Phase Context

Phase 2 trials begin testing efficacy in a larger patient group (100–300). This is often where biotech binary events occur — positive Phase 2 data can significantly advance a company's pipeline narrative, while failures can be terminal for a program.

Status & Expected Data

Currently recruiting: the trial is enrolling patients. A data readout is not expected until after enrollment closes and the follow-up period is complete.

Enrolled: 377 participants

Sponsor Catalyst Profile

AbbVie Inc (ABBV) is the sponsoring company for this trial. BiotechSign currently grades this company C (58/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

ABBV Full Pipeline →All Companies →

Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.